Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report issued on Saturday, Wall Street Zen reports.
Other equities analysts have also issued reports about the company. UBS Group set a $4.00 price target on Aardvark Therapeutics in a research note on Monday, October 19th. Royal Bank Of Canada set a $2.50 price objective on Aardvark Therapeutics in a research report on Friday, October 23rd. BTIG Research dropped coverage on Aardvark Therapeutics in a research report on Monday, October 12th. They set a “neutral” rating on the stock. Raymond James Financial restated a “market perform” rating on shares of Aardvark Therapeutics in a research report on Friday. Finally, HC Wainwright cut their target price on Aardvark Therapeutics from $4.00 to $2.00 and set a “hold” rating for the company in a research note on Monday, October 26th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $11.56.
Get Our Latest Research Report on Aardvark Therapeutics
Aardvark Therapeutics Price Performance
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.19). As a group, sell-side analysts expect that Aardvark Therapeutics will post -3.05 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Aardvark Therapeutics news, insider Nelson Sun sold 62,000 shares of Aardvark Therapeutics stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $5.18, for a total transaction of $321,160.00. Following the sale, the insider directly owned 35,475 shares of the company’s stock, valued at approximately $183,760.50. The trade was a 63.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 17.80% of the company’s stock.
Institutional Trading of Aardvark Therapeutics
Several institutional investors have recently bought and sold shares of AARD. BlackRock Inc. acquired a new position in Aardvark Therapeutics during the second quarter worth $1,077,000. Marshall Wace LLP lifted its holdings in shares of Aardvark Therapeutics by 593.0% during the third quarter. Marshall Wace LLP now owns 132,204 shares of the company’s stock valued at $697,000 after acquiring an additional 113,128 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Aardvark Therapeutics in the 1st quarter valued at $267,000. J. Goldman & Co LP acquired a new stake in shares of Aardvark Therapeutics in the 2nd quarter valued at $233,000. Finally, Ieq Capital LLC bought a new stake in shares of Aardvark Therapeutics in the 2nd quarter worth about $221,000.
About Aardvark Therapeutics
Aardvark Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California. It develops oral medicines for metabolic disorders, with a focus on conditions involving excessive hunger and disrupted energy balance. The company’s lead candidate, ARD-101, is an investigational oral therapy designed to activate bitter taste receptors in the gut and influence gut-brain signaling. Aardvark has studied the candidate for hyperphagia, or excessive hunger, associated with Prader-Willi syndrome and hypothalamic obesity.
Featured Stories
- Five stocks we like better than Aardvark Therapeutics
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Aardvark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aardvark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
